Virtual Poster Session in Neuroendocrine Tumors - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in Neuroendocrine Tumors

Practical Application of Key Data Presented During the 2019 Neuroendocrine Cancer Meeting in Barcelona

Not a member of My prIME? Join now for instant access.

View virtual poster presentations and downloadable slides covering the most up-to-date clinical trial data from the 2019 Annual Neuroendocrine Cancer Meeting in Barcelona.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Mar 13, 2019

Expiration Date

Mar 13, 2020

Wendy Martin, RN, MSc

Abstract #H14: Development of a New and Improved Delivery System (DS) for Lanreotide Autogel/ Depot (LAN) to Further Enhance Patient Care

Featured Expert: Wendy Martin, RN, MSc

Leonidas Apostolidis, MD

Abstract #I01: Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium

Featured Expert: Leonidas Apostolidis, MD

Jaume Capdevila, MD, PhD

Abstract #I03: Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors

Featured Expert: Jaume Capdevila, MD, PhD

Dieter Hörsch, MD, PhD

Abstract #J07: Long-Term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study

Featured Expert: Dieter Hörsch, MD, PhD

Piero Ferolla, MD, PhD

Abstract #M03: Population Data from Atlant, Phase 2 Study Combination Trial between Long Acting Somatostatin Analogue (SSA) Lanreotide (LAN) and Temozolomide (TMZ) in Progressive Thoracic (Lung/Thymus) Well Differentiated NET (Carcinoid) (TNETS)

Featured Expert: Piero Ferolla, MD, PhD

  • Leonidas Apostolidis, MDUniversity Hospital Heidelberg
    Heidelberg, Germany
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Piero Ferolla, MD, PhDUniversity of Perugia
    Perugia, Italy
  • Dieter Hörsch, MD, PhDCenter for Neuroendocrine Tumors Bad Berka
    Bad Berka, Germany
  • Wendy Martin, RN, MScKings College Hospital NHS Trust
    London, United Kingdom

This educational activity is designed for medical oncologists, endocrinologists, gastroenterologists and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors (NETs).

Upon completion of this educational activity, participants should be able to:

  • Describe recent findings on the contemporary use of somatostatin analog therapy in the management of NETs/neuroendocrine neoplasms (NENs)
  • Assess clinical trial data describing the use of treatment options for carcinoid syndrome

This educational activity is supported by Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This educational activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

[SPEAKER NAME 1] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

[SPEAKER NAME 2] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

[SPEAKER NAME 3] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

[SPEAKER NAME 4] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

[SPEAKER NAME 5] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.